452 Preliminary analysis of a real-world study (RWS) of camrelizumab treatment in primary liver cancer (PLC)

• Published in: Journal for immunotherapy of cancer Vol. 9; no. Suppl 2; pp. A479 - A480
• Main Authors: Chen, Zhendong, Wang, Nianfei, Luo, Dayong, Jiang, Bo, Yuan, Mu, Li, Xinzhong, Yao, Chunmei, Qian, Hong, Kan, Qingsheng, Wang, Erxuan
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd 01.11.2021; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Cancer therapies; Chemotherapy; Immunotherapy; Inhibitor drugs; Liver cancer; Monoclonal antibodies; Patients; Regular and Young Investigator Award Abstracts; Targeted cancer therapy

BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized the landscape of PLC management at all evolutionary stages.1 As an anti-programmed cell death-1 (PD-1) antibody, camrelizumab monotherapy and in combination with apatinib, an anti-angiogenetic tyrosine kinase inhibitor of vascular end...